- 同花顺特色产品
- 〈高级诊股〉 全方位深度分析，提供明确投资建议
- 短期趋势：
弱势下跌过程中，可逢高卖出，暂不考虑买进。
- 中期趋势：
下跌有所减缓，仍应保持谨慎。
- 长期趋势：
已有461家主力机构披露2025-06-30报告期持股数据，持仓量总计3.25亿股，占流通A股55.60%
- 波段诊断：
-
技术面诊股
诊断结果：4.3技术面打败了43%的股票
技术面评分前10的股票
近期的平均成本为35.63元。空头行情中，目前反弹趋势有所减缓，投资者可适当关注。
平均成本
近期的平均成本为35.63元。
[{"text":"\u5e73\u5747\u6210\u672c","value":"35.63","date":1764575489,"color":"0x9f0ba1"}]
市场表现
过去10个交易日，该股走势明显跑输大盘，接近行业平均水平。
[{"date":"2025.12.02","stock":"-1.31","trade":"-1.08","ind":"-0.68"},{"date":"2025.12.01","stock":"1.24","trade":"0.07","ind":"1.25"},{"date":"2025.11.28","stock":"-0.97","trade":"-0.17","ind":"0.85"},{"date":"2025.11.27","stock":"-0.64","trade":"-0.20","ind":"-0.25"},{"date":"2025.11.26","stock":"0.84","trade":"1.10","ind":"1.02"},{"date":"2025.11.25","stock":"0.65","trade":"2.23","ind":"1.53"},{"date":"2025.11.24","stock":"0.31","trade":"1.45","ind":"0.37"},{"date":"2025.11.21","stock":"-1.80","trade":"-3.83","ind":"-3.41"},{"date":"2025.11.20","stock":"0.36","trade":"-0.26","ind":"-0.76"},{"date":"2025.11.19","stock":"-0.80","trade":"-1.93","ind":"-0.00"},{"date":"2025.11.18","stock":"-0.66","trade":"-1.16","ind":"-0.92"},{"date":"2025.11.17","stock":"-2.82","trade":"-1.58","ind":"-0.11"},{"date":"2025.11.14","stock":"0.03","trade":"0.97","ind":"-1.93"},{"date":"2025.11.13","stock":"0.19","trade":"1.58","ind":"1.78"},{"date":"2025.11.12","stock":"0.56","trade":"0.46","ind":"-0.36"},{"date":"2025.11.11","stock":"-0.56","trade":"0.64","ind":"-1.03"},{"date":"2025.11.10","stock":"0.29","trade":"1.26","ind":"0.18"},{"date":"2025.11.07","stock":"1.85","trade":"-0.31","ind":"-0.36"},{"date":"2025.11.06","stock":"0.46","trade":"-0.47","ind":"1.73"},{"date":"2025.11.05","stock":"0.41","trade":"0.13","ind":"0.37"},{"date":"2025.11.04","stock":"-0.65","trade":"-1.91","ind":"-1.71"}]
丽珠集团,深证成指,化学制药指数
压力支撑
该股压力位为35.66元，支撑位为35.39元。
[{"text":"\u538b\u529b\u4f4d","value":"35.66","date":1764604800,"color":"0x9f0ba1"},{"text":"\u652f\u6491\u4f4d","value":"35.39","date":1764604800,"color":"0x0b52a1"}]
多空趋势
空头行情中，目前反弹趋势有所减缓，投资者可适当关注。
macd
kdj
boll
asi
bias
rsi
wr
vr
资金面诊股
诊断结果：2.3资金面打败了12%的股票
主力控盘前10的股票
行业资金
化学制药行业， 近5日资金总体呈流出状态，请投资者谨慎关注该行业的个股。
更新时间：12月02日 20:30
| 机构今日流向(万元) | -2063.48 | 机构5日流向(万元) | -5517.71 |
| 机构10日流向(万元) | -9883.99 | 机构20日流向(万元) | -17127.62 |
机构持仓
2025-06-30 与 2024-12-31 相比，主力机构持仓量减少1635.75万股，其中基金净减仓78家，主力净增仓62家，暂未发现中长期投资价值。
截止2025-06-30，共461家主力机构（基金455家，社保基金1家，一般法人4家，保险公司1家），持仓量总计32476.57万股，占流通A股55.60%
其中，基金持仓与2024-12-31相比：
增仓：75家 ，增持 901.95万股
减仓：153家 ，减持 701.12万股
新出现在主力名单中：204家 ，持有2434.07万股
从主力名单中消失：142家 ，原持有2234.51万股
其中，基金持仓与2024-12-31相比：
增仓：75家 ，增持 901.95万股
减仓：153家 ，减持 701.12万股
新出现在主力名单中：204家 ，持有2434.07万股
从主力名单中消失：142家 ，原持有2234.51万股
消息面诊股
诊断结果：5.5消息面打败了4%的股票
今日有利好新闻的公司
近期该股消息面总体多空平衡，没有较强的利好或利空趋势。
更多>>个股资讯
- 丽珠医药截至11月末累计回购共计1619.33万股
2025-12-01 - 2025年司美格鲁肽原料药竞争格局
2025-12-01 - 行业周报|化学制药指数涨4.46%, 跑赢上证指数
2025-11-28 - 丽珠集团：P-CAB产品片剂已报产，注射剂进入II
2025-11-28 - 丽珠集团：11月27日获融资买入990.18万元
2025-11-28 - 丽珠集团：11月25日获融资买入1067.87万元
2025-11-26 - A股年内累计回购超1300亿元 超百家实施公司股价
2025-11-26 - 回购超1亿元+股价回调！这些潜力股暗藏修复机会？
2025-11-25 - 丽珠集团：11月18日获融资买入1586.66万元
2025-11-19 - 机构评级|国泰海通证券给予丽珠集团“增持”评级
2025-11-18
消息列表
| 一般消息 | 股东大会 | 临时股东大会 | 2025-11-11 |
| 一般消息 | 募资投向 | 公司购买资产 | 2025-08-23 |
| 一般消息 | 重大事项 | 关联交易 | 2025-08-23 |
| 一般消息 | 分红转增 | 不分配不转增 | 2025-08-21 |
| 一般消息 | 高管变动 | 因工作调整原因 | 2025-08-20 |
| 利好 | 重大事项 | 参股拟上市公司或非上市公司金融机构 | 2025-06-30 |
| 一般消息 | 募资投向 | 公司购买资产 | 2025-05-23 |
| 一般消息 | 高管变动 | 因工作调整原因 | 2025-04-23 |
| 一般消息 | 高管变动 | 因个人发展原因 | 2025-03-31 |
| 利好 | 分红转增 | 10派11元(含税) | 2025-03-27 |
| 一般消息 | 重大事项 | 关联交易 | 2025-01-02 |
| 一般消息 | 高管变动 | 因工作调整原因 | 2024-12-31 |
| 利好 | 重大事项 | 参股拟上市公司或非上市公司金融机构 | 2024-12-31 |
一年消息统计
| 所有消息 | 重大消息 | 非重大消息 | |
| 利好 | 3条 | 0条 | 3条 |
| 利空 | 0条 | 0条 | 0条 |
行业面诊股
诊断结果：5.2行业面打败了69%的股票
化学制药行业最新资金流向
近10日来该行业走势不明显，明显跑输大盘。最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
行业走势
近10日来该行业走势不明显，明显跑输大盘。
[{"date":"2025.12.02","price":"-0.68","value":"-1.08"},{"date":"2025.12.01","price":"1.25","value":"0.07"},{"date":"2025.11.28","price":"0.85","value":"-0.17"},{"date":"2025.11.27","price":"-0.25","value":"-0.20"},{"date":"2025.11.26","price":"1.02","value":"1.10"},{"date":"2025.11.25","price":"1.53","value":"2.23"},{"date":"2025.11.24","price":"0.37","value":"1.45"},{"date":"2025.11.21","price":"-3.41","value":"-3.83"},{"date":"2025.11.20","price":"-0.76","value":"-0.26"},{"date":"2025.11.19","price":"-0.00","value":"-1.93"},{"date":"2025.11.18","price":"-0.92","value":"-1.16"},{"date":"2025.11.17","price":"-0.11","value":"-1.58"},{"date":"2025.11.14","price":"-1.93","value":"0.97"},{"date":"2025.11.13","price":"1.78","value":"1.58"},{"date":"2025.11.12","price":"-0.36","value":"0.46"},{"date":"2025.11.11","price":"-1.03","value":"0.64"},{"date":"2025.11.10","price":"0.18","value":"1.26"},{"date":"2025.11.07","price":"-0.36","value":"-0.31"},{"date":"2025.11.06","price":"1.73","value":"-0.47"},{"date":"2025.11.05","price":"0.37","value":"0.13"},{"date":"2025.11.04","price":"-1.71","value":"-1.91"}]
深证成指,化学制药行业
行业排名
| 排名 | 股票名称 | 1月涨跌幅 | 5日涨跌幅 | 评分 |
|---|---|---|---|---|
| 1 | 富祥药业 | 51.74% | -1.65% | 4.3分 |
| 2 | 康芝药业 | 38.67% | -1.30% | 5.7分 |
| 3 | 海南海药 | 29.47% | -4.29% | 5.7分 |
| 4 | *ST苏吴 | 29.17% | 27.84% | 5.7分 |
| 5 | 广济药业 | 27.31% | 7.20% | 5.9分 |
| 6 | 北大医药 | 23.38% | 8.89% | 5.6分 |
| 8 | 悦康药业 | 18.46% | 1.33% | 6.0分 |
| 10 | 常山药业 | 15.24% | 7.32% | 5.8分 |
| 12 | 福元医药 | 11.81% | 11.66% | 5.5分 |
| 14 | 新华制药 | 9.49% | 1.52% | 5.6分 |
| 16 | 民生健康 | 8.79% | 0.94% | 4.1分 |
| 18 | 金石亚药 | 7.94% | -4.45% | 5.5分 |
| 20 | 京新药业 | 7.43% | -6.87% | 4.9分 |
| 22 | 海欣股份 | 6.56% | 7.98% | 5.9分 |
| 24 | 神奇制药 | 5.21% | 1.33% | 6.0分 |
| 26 | 信立泰 | 4.73% | 1.81% | 5.5分 |
| 28 | 亨迪药业 | 4.61% | -6.76% | 4.7分 |
| 30 | 华东医药 | 4.09% | 3.86% | 5.6分 |
| 32 | 健康元 | 3.32% | 0.89% | 5.9分 |
| 34 | 泽璟制药 | 3.16% | -0.62% | 6.3分 |
| 36 | 河化股份 | 3.10% | -5.55% | 6.0分 |
| 38 | 通化金马 | 2.61% | 5.79% | 4.7分 |
| 40 | 华仁药业 | 2.31% | 4.12% | 5.8分 |
| 42 | 东北制药 | 1.96% | 2.69% | 6.0分 |
| 44 | 福安药业 | 1.31% | 2.65% | 5.6分 |
| 46 | 津药药业 | 1.16% | 0.69% | 5.5分 |
| 48 | *ST赛隆 | 1.09% | 6.45% | 5.0分 |
| 50 | 新和成 | 0.62% | 1.41% | 4.7分 |
| 52 | 恩华药业 | 0.37% | 2.71% | 4.7分 |
| 54 | 科伦药业 | 0.15% | 1.98% | 5.8分 |
| 56 | 海翔药业 | -0.32% | -0.16% | 5.0分 |
| 58 | 哈药股份 | -0.55% | 0.83% | 5.2分 |
| 60 | 海普瑞 | -0.58% | 2.12% | 4.7分 |
| 62 | 同和药业 | -0.61% | -0.37% | 4.6分 |
| 64 | 溢多利 | -0.85% | -1.41% | 4.0分 |
| 66 | 罗欣药业 | -0.92% | -0.56% | 5.4分 |
| 68 | 汉商集团 | -1.10% | 0.00% | 5.4分 |
| 70 | 天新药业 | -1.48% | -1.33% | 4.7分 |
| 72 | 首药控股 | -1.66% | -6.85% | 4.3分 |
| 74 | 天宇股份 | -1.79% | -1.08% | 4.7分 |
| 76 | ST诺泰 | -2.08% | -2.46% | 4.4分 |
| 78 | 奥翔药业 | -2.30% | -1.41% | 4.8分 |
| 80 | 华特达因 | -2.47% | -2.75% | 5.7分 |
| 82 | 华润双鹤 | -2.55% | 0.37% | 5.7分 |
| 84 | 东诚药业 | -2.66% | 1.70% | 4.5分 |
| 86 | 仙琚制药 | -2.75% | -3.06% | 4.4分 |
| 88 | 鲁抗医药 | -3.35% | -1.51% | 4.8分 |
| 90 | 奥锐特 | -3.37% | 3.00% | 5.1分 |
| 92 | 苑东生物 | -3.55% | 4.30% | 5.2分 |
| 94 | 浙江医药 | -3.58% | 0.00% | 5.1分 |
| 96 | - | -3.94% | -0.36% | 分 |
| 98 | 复星医药 | -4.28% | -1.46% | 5.3分 |
| 100 | 仟源医药 | -4.47% | -0.85% | 5.0分 |
| 102 | 宣泰医药 | -4.79% | -1.34% | 4.8分 |
| 104 | 艾力斯 | -5.08% | -0.98% | 5.5分 |
| 106 | 誉衡药业 | -5.29% | 0.00% | 5.2分 |
| 108 | 金城医药 | -5.50% | -2.19% | 4.3分 |
| 110 | 司太立 | -5.77% | -1.78% | 4.1分 |
| 112 | 博瑞医药 | -6.03% | -0.65% | 5.4分 |
| 114 | 共同药业 | -6.55% | -2.22% | 4.3分 |
| 116 | 一品红 | -6.64% | -10.31% | 4.4分 |
| 118 | 益方生物 | -6.98% | -1.11% | 5.5分 |
| 120 | 北陆药业 | -7.06% | -1.33% | 4.8分 |
| 122 | 新诺威 | -7.14% | -2.52% | 4.0分 |
| 124 | 德展健康 | -7.26% | -1.68% | 3.3分 |
| 126 | - | -7.87% | 0.16% | 分 |
| 128 | 富士莱 | -8.36% | -1.56% | 4.0分 |
| 130 | 汇宇制药 | -9.03% | -3.43% | 4.5分 |
| 132 | 易明医药 | -9.23% | -3.06% | 4.8分 |
| 134 | 泰恩康 | -9.31% | -4.54% | 4.3分 |
| 136 | 纳微科技 | -9.72% | -2.26% | 4.7分 |
| 138 | 微芯生物 | -9.84% | 1.02% | 4.9分 |
| 140 | 川宁生物 | -10.73% | -2.18% | 4.1分 |
| 142 | 翰宇药业 | -11.18% | 0.65% | 5.0分 |
| 144 | 上海谊众 | -11.89% | -3.46% | 4.9分 |
| 146 | - | -12.96% | -0.97% | 分 |
| 148 | - | -13.28% | -0.72% | 分 |
| 150 | 贝达药业 | -13.60% | -2.35% | 4.0分 |
| 152 | 多瑞医药 | -13.97% | 0.08% | 4.5分 |
| 154 | 广生堂 | -15.71% | -4.36% | 3.9分 |
| 156 | 亚太药业 | -17.22% | -2.72% | 4.7分 |
| 158 | 舒泰神 | -25.05% | -7.16% | 3.5分 |
行业评级
最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
- 综合评级
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 中信证券 | 2012-09-10 | 增持 | 增持 |
| 招商证券 | 2012-09-08 | 增持 | 增持 |
| 航天证券 | 2012-09-06 | 增持 | - |
| 中银国际 | 2012-09-05 | 增持 | - |
| 齐鲁证券 | 2012-09-05 | 增持 | - |
更多>>行业资讯
- 2012-09-13亿利能源股权质押登记
- 2012-09-13太极集团修改《公司章程》
- 2012-09-13人福医药获得国家补助资金
- 2012-09-13常山药业：归还暂时用于补充流动资金的闲置募集资金
- 2012-09-13贵州百灵：公司与济南百诺医药科技开发有限公司签订技
- 2012-09-13振东制药山西省第三建筑工程公司承建山西振东泰盛制药
- 2012-09-13双成药业：战略合作框架协议进展
- 2012-09-13佛慈制药：签订推荐恢复上市、委托代办股份转让协议
- 2012-09-13昊海生科IPO资产被疑是大江股份上市募投项目
- 2012-09-13泰格医药涨势猛 业务有望快速扩张
基本面诊股
[ 截止日期：2025-09-30 ]公司经营
盈利能力：很强，位居行业前列,建议强烈关注，两项指标的行业排名分别为 15/219 ， 36/219。
[{"date":"2025-09-30","value":"12.61","vol":"1.46"},{"date":"2025-06-30","value":"9.30","vol":"1.21"},{"date":"2025-03-31","value":"4.54","vol":"-0.17"},{"date":"2024-12-31","value":"14.77","vol":"19.51"},{"date":"2024-09-30","value":"11.86","vol":"4.61"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 净资产收 益率(%) |
12.61 | 9.30 | 4.54 | 14.77 | 11.86 |
| 行业(%) | 1.46 | 1.21 | -0.17 | 19.51 | 4.61 |
该指标值越高，盈利能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"66.39","vol":"49.47"},{"date":"2025-06-30","value":"66.02","vol":"49.43"},{"date":"2025-03-31","value":"64.96","vol":"49.23"},{"date":"2024-12-31","value":"65.45","vol":"50.77"},{"date":"2024-09-30","value":"65.81","vol":"50.51"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 销售毛利 率(%) |
66.39 | 66.02 | 64.96 | 65.45 | 65.81 |
| 行业(%) | 49.47 | 49.43 | 49.23 | 50.77 | 50.51 |
该指标值越高，盈利能力越强，行业排名越靠前。
成长能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 63/219 ， 65/219。
[{"date":"2025-09-30","value":"0.38","vol":"141.76"},{"date":"2025-06-30","value":"-0.17","vol":"78.53"},{"date":"2025-03-31","value":"-1.92","vol":"-0.84"},{"date":"2024-12-31","value":"-4.97","vol":"17.76"},{"date":"2024-09-30","value":"-5.94","vol":"45.69"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 营业收入同 比增长率(%) |
0.38 | -0.17 | -1.92 | -4.97 | -5.94 |
| 行业(%) | 141.76 | 78.53 | -0.84 | 17.76 | 45.69 |
该指标值越高，成长能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"4.86","vol":"-5.21"},{"date":"2025-06-30","value":"9.40","vol":"56.29"},{"date":"2025-03-31","value":"4.75","vol":"-21.21"},{"date":"2024-12-31","value":"5.50","vol":"-20.55"},{"date":"2024-09-30","value":"4.44","vol":"-32.33"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 净利润同比 增长率(%) |
4.86 | 9.40 | 4.75 | 5.50 | 4.44 |
| 行业(%) | -5.21 | 56.29 | -21.21 | -20.55 | -32.33 |
该指标值越高，成长能力越强，行业排名越靠前。
营运能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 43/219 ， 68/219。
[{"date":"2025-09-30","value":"0.37","vol":"0.31"},{"date":"2025-06-30","value":"0.26","vol":"0.21"},{"date":"2025-03-31","value":"0.13","vol":"0.10"},{"date":"2024-12-31","value":"0.48","vol":"0.43"},{"date":"2024-09-30","value":"0.36","vol":"0.33"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 总资产周 转率(次) |
0.37 | 0.26 | 0.13 | 0.48 | 0.36 |
| 行业(次) | 0.31 | 0.21 | 0.10 | 0.43 | 0.33 |
该指标值越高，营运能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"1.68","vol":"1.95"},{"date":"2025-06-30","value":"1.15","vol":"1.31"},{"date":"2025-03-31","value":"0.57","vol":"0.67"},{"date":"2024-12-31","value":"2.01","vol":"3.22"},{"date":"2024-09-30","value":"1.53","vol":"2.18"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 存货增长 率(次) |
1.68 | 1.15 | 0.57 | 2.01 | 1.53 |
| 行业(次) | 1.95 | 1.31 | 0.67 | 3.22 | 2.18 |
该指标值越高，营运能力越强，行业排名越靠前。
现金流能力：数据暂时不全，请后续关注
[{"date":"2025-09-30","value":"29.48","vol":"4.36"},{"date":"2025-06-30","value":"31.13","vol":"2.81"},{"date":"2025-03-31","value":"22.79","vol":"-28.76"},{"date":"2024-12-31","value":"24.57","vol":"-371.46"},{"date":"2024-09-30","value":"27.79","vol":"-9.87"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 现金流量净额/营业收入 | 29.48 | 31.13 | 22.79 | 24.57 | 27.79 |
| 行业 | 4.36 | 2.81 | -28.76 | -371.46 | -9.87 |
该指标值越高，现金流能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"","vol":"0.00"},{"date":"2025-06-30","value":"1.23","vol":"1.72"},{"date":"2025-03-31","value":"","vol":"0.00"},{"date":"2024-12-31","value":"0.91","vol":"1.99"},{"date":"2024-09-30","value":"","vol":"0.00"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 资本支出／折旧和摊销 | - | 1.23 | - | 0.91 | - |
| 行业 | 0.00 | 1.72 | 0.00 | 1.99 | 0.00 |
该指标值越低，现金流能力越强，行业排名越靠前。
短期偿债能力：很强，位居行业前列,建议强烈关注，两项指标的行业排名分别为 17/219 ， 86/219。
[{"date":"2025-09-30","value":"2.25","vol":"3.49"},{"date":"2025-06-30","value":"2.19","vol":"3.67"},{"date":"2025-03-31","value":"2.28","vol":"3.59"},{"date":"2024-12-31","value":"2.15","vol":"3.34"},{"date":"2024-09-30","value":"1.84","vol":"3.66"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 流动比率 |
2.25 | 2.19 | 2.28 | 2.15 | 1.84 |
| 行业 | 3.49 | 3.67 | 3.59 | 3.34 | 3.66 |
该指标值越接近2，短期偿债能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"1.95","vol":"2.74"},{"date":"2025-06-30","value":"1.90","vol":"2.89"},{"date":"2025-03-31","value":"1.97","vol":"2.81"},{"date":"2024-12-31","value":"1.86","vol":"2.64"},{"date":"2024-09-30","value":"1.58","vol":"2.92"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 速动比率 |
1.95 | 1.90 | 1.97 | 1.86 | 1.58 |
| 行业 | 2.74 | 2.89 | 2.81 | 2.64 | 2.92 |
该指标值越接近1，短期偿债能力越强，行业排名越靠前。
长期偿债能力：尚可，接近行业平均，可适当关注，两项指标的行业排名分别为 49/219 ， 56/219。
[{"date":"2025-09-30","value":"37.37","vol":"33.75"},{"date":"2025-06-30","value":"38.26","vol":"33.79"},{"date":"2025-03-31","value":"37.21","vol":"34.04"},{"date":"2024-12-31","value":"39.05","vol":"34.19"},{"date":"2024-09-30","value":"40.04","vol":"33.02"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 资产负债 率(%) |
37.37 | 38.26 | 37.21 | 39.05 | 40.04 |
| 行业(%) | 33.75 | 33.79 | 34.04 | 34.19 | 33.02 |
该指标值越接近50%，长期偿债能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"0.66","vol":"0.94"},{"date":"2025-06-30","value":"0.68","vol":"0.88"},{"date":"2025-03-31","value":"0.64","vol":"1.46"},{"date":"2024-12-31","value":"0.69","vol":"0.84"},{"date":"2024-09-30","value":"0.70","vol":"0.73"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 产权比率 (%) |
0.66 | 0.68 | 0.64 | 0.69 | 0.70 |
| 行业(%) | 0.94 | 0.88 | 1.46 | 0.84 | 0.73 |
该指标值越高，长期偿债能力越强，行业排名越靠前。
机构评级
最近60个交易日，机构评级以买入为主，认为该股票非常值得关注。
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 国泰海通证券 | 2025-11-18 | 买入 | |
| 中信建投证券 | 2025-11-06 | 买入 | 买入 |
| 国信证券 | 2025-11-03 | 买入 | 买入 |
| 甬兴证券 | 2025-11-03 | 买入 | |
| 东海证券 | 2025-10-31 | 买入 | |
| 太平洋 | 2025-10-28 | 买入 |
机构预测
机构预测该股2025年每股收益与前一年相同，长期投资价值一般。
[{"date":"2021","yellowRectValue":"17.76","blueLineValue":"","type":""},{"date":"2022","yellowRectValue":"19.09","blueLineValue":"","type":""},{"date":"2023","yellowRectValue":"19.54","blueLineValue":"","type":""},{"date":"2024","yellowRectValue":"20.61","blueLineValue":"","type":""},{"date":"2025","yellowRectValue":"22.57","blueLineValue":"2.49","type":"YC"}]